DAVID POPLACK to Neuroectodermal Tumors, Primitive, Peripheral
This is a "connection" page, showing publications DAVID POPLACK has written about Neuroectodermal Tumors, Primitive, Peripheral.
Connection Strength
0.027
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
Score: 0.010
-
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996 Feb; 14(2):362-72.
Score: 0.009
-
A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. Invest New Drugs. 1996; 13(4):337-42.
Score: 0.009